ZERO-MIGRAINE

 

DAYS ARE POSSIBLE

 

THE FORGET-YOU-GET

MIGRAINE Medicine

QULIPTA helps give your patients that forget-you-get migraine feeling. Across 12 weeks, QULIPTA 60 mg reduced attacks for both episodic and chronic migraine patients.

EM primary endpoint: Significant -4.2 monthly migraine day reduction from 7.8 baseline (n=222; P<0.001) vs -2.5 from 7.5 baseline for placebo (n=214)

CM primary endpoint: Significant -6.9 monthly migraine day reduction from 19.2 baseline (n=256; P<0.001) vs -5.1 from 18.9 baseline for placebo (n=246)

The only oral CGRP treatment proven to prevent both episodic and chronic migraine

NOW APPROVED FOR CHRONIC MIGRAINE

*Specific to episodic migraine.

Eligibility: Available to patients with commercial insurance coverage for QULIPTA who meet eligibility criteria. This copay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit QULIPTASavingsCard.com or call 1-855-QULIPTA (1-855-785-4782) for more information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy.

Data from Phase 3 ADVANCE EM pivotal study.

§Data from Phase 3 PROGRESS CM pivotal study.

Data from 52-week, open-label, long term safety study for EM.

CGRP=calcitonin gene-related peptide; CM=chronic migraine; EM=episodic migraine.